Tagged with Europe,

Europe Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to carve out a slice of this huge growth market. Those who made a bet on obesity years in advance are…

Portugal Boehringer Ingelheim has a 60-year history in Portugal and, despite challenges in terms of market access and reimbursement delays, remains fully committed to providing innovative healthcare solutions in the country. General Manager Sandra Marques outlines how the firm has established itself as a major player in Portugal’s prescription retail market,…

Europe The European Medicines Agency (EMA) recommended 77 drugs for marketing authorisation in 2023, including 39 new active substances, coming up behind the FDA’s record 55 new drug approvals last year. Cancer led the roster of EMA green lights with 25 authorisations, including nine therapies the agency has discerned as major…

Spain Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around COVID-19, Spain has continued consolidating its status as a leading clinical trials hub and registered over 900 trials in 2022,…

Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…

France With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination for international investments, France is looking to boost innovation, attracting the largest number of R&D centres in Europe in 2022,…

Portugal Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines manufacturers embedded in the country are keen to point out that access to the latest drugs remains a big issue…

Europe A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe and beyond.   The knowledge and infrastructure required to unlock rare disease “white spots,” diseases where there is currently no…

Portugal Dr Maria Mota, executive director at Portugal’s Institute of Molecular Medicine (iMM), shares how the non-profit institute generated its own circular economy during the COVID-19 pandemic and saved the Portuguese government some EUR 15 million thanks to its in-house developed PCR tests. She describes the expanson of the iMM’s focus…

Portugal Pedro Moura, managing director at Merck Portugal, outlines the company’s unique presence and the Portuguese affiliate’s diverse portolio. He discusses the challenges around access to innovation in Portugal, where only 44 percent of the drugs approved in the European Union make it to the local market and time to reimbursement…

Portugal The top 10 pharma companies in Portugal ranked by sales value in both the hospital and pharmacy markets. These charts are from IQVIA and are based on a moving annual total up to October 2023. Household Big Pharma names like Janssen (recently rebranded as Johnson & Johnson Innovative Medicines), Roche,…

Portugal Country manager at Lundbeck Portugal, Sara Barros, came to the Danish company after a number of management positions at larger pharma companies and took on the leadership of its local affiliate about three years ago. She comments on the shift in societal attitudes towards mental health, discusses Portugal’s psychiatric care…